New inhaled therapy for lung blood pressure passes first safety hurdle
NCT ID NCT06429930
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of a single inhaled dose of L608 in 32 healthy volunteers. L608 is a liposomal formulation designed to treat pulmonary arterial hypertension, a condition of high blood pressure in the lungs. The study compares different doses against a placebo to check for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
L608 (liposomal inhalation suspension)
What this could lead to
If safe, this could lead to a new inhaled treatment for pulmonary arterial hypertension, offering a more targeted way to manage the disease.
What could go wrong
This is a very early Phase 1 safety study in only 32 healthy people, not patients. It tests low doses and may not show benefit or translate into an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NZCR Ltd (New Zealand Clinical Research)
RECRUITINGChristchurch, 8011, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••